{"public_id":"co_4a7de83722ac81733f577724199b6b85","status":"active","merged_into_public_id":null,"resolved_public_id":"co_4a7de83722ac81733f577724199b6b85","name":"systemic adverse events","description":"Safety outcome measuring systemic adverse events after vaccination; higher rates were noted in adults/elderly but not in children.","aliases":["systemic AEs"],"types":["safety outcome"],"contributors":[{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["extraction"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":2},"verdict_counts":{"approve":2,"reject":0},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":241185914,"title":"Comparative efficacy and safety of vaccines to prevent seasonal influenza: A systematic review and network meta-analysis","citation_count":56,"url":"https://sah.borca.ai/papers/241185914"}],"claims":[{"public_id":"cl_cc73927bf1f3bb2c8ca2d7b78131d7a8","text":"In adults and elderly, several vaccines including 3-IIV, 3-IIV HD, 3-IIV ID, 3-IIV MF59/AS03-adj, 4-IIV, 4-IIV MF59/AS03-adj, 4-RIV, 3-LAIV and 4-LAIV were associated with higher rates of systemic adverse events compared to placebo (RR 1.15 to 1.5), while in children the systemic AE rate after vaccination was not significantly higher than placebo.","corpus_id":241185914,"url":"https://sah.borca.ai/claims/cl_cc73927bf1f3bb2c8ca2d7b78131d7a8"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_4a7de83722ac81733f577724199b6b85","url":"https://sah.borca.ai/concepts/co_4a7de83722ac81733f577724199b6b85"}